The EPCORE FL-1 trial evaluated epcoritamb plus lenalidomide and rituximab versus plus lenalidomide and rituximab for ...
At ASH 2025, researchers reported on 3-year efficacy and safety of lisocabtagene maraleucel in follicular lymphoma patients being treated in the third-line setting or later.
In the phase 2 Smart Stop trial, researchers investigated the feasibility of achieving durable complete responses in DLBCL without the use of chemotherapy.
In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback